Literature DB >> 10193428

Cytokine flow cytometry differentiates the clinical status of multiple sclerosis (MS) patients.

S Inogés1, J Merino, E Bandrés, P De Castro, M L Subirá, A Sánchez-Ibarrola.   

Abstract

In this study we have examined intracellular cytokines in peripheral blood mononuclear cells (PBMC) of MS patients by flow cytometry (cytokine flow cytometry). MS progressive patients showed an increased number of cells producing interferon-gamma (IFN-gamma) after activation with phorbol 12-myristate 13-acetate and ionomycin, compared with patients with clinically inactive forms (P < 0001) and with healthy controls (P = 0001). These cells belonged to the CD4+ and CD8+ subsets in similar proportions. Clinically inactive patients showed a lower level of cells producing IL-2 than controls (P = 0.03) and active MS patients (P = 0.03). Most IL-2-producing cells were CD4+ lymphocytes, although a small part of the IL-2 was also produced by CD8+ cells. The percentage of cells producing simultaneously IL-2 and IFN-gamma was increased in active MS and they were mainly CD4+ lymphocytes. No differences in the production of IL-4 were observed between groups. However, we found an increased IL-10 production in clinically active MS patients (P = 0.03). Treatment with IFN-beta of active MS patients showed lower levels of cytokines when compared with untreated MS patients. This methodological approach could help in the follow up and therapeutic monitoring of MS patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193428      PMCID: PMC1905256          DOI: 10.1046/j.1365-2249.1999.00816.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels.

Authors:  J L Trotter; K G Collins; R C van der Veen
Journal:  J Neuroimmunol       Date:  1991-07       Impact factor: 3.478

2.  Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis.

Authors:  J L Trotter; D B Clifford; C B Anderson; R C van der Veen; B C Hicks; G Banks
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

3.  Interferon production by lymphocytes from multiple sclerosis and non-MS patients.

Authors:  D R Tovell; I A McRobbie; K G Warren; D L Tyrrell
Journal:  Neurology       Date:  1983-05       Impact factor: 9.910

4.  Response to and production of interleukin 2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis.

Authors:  J E Merrill; C Mohlstrom; C Uittenbogaart; V Kermaniarab; G W Ellison; L W Myers
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

5.  Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis.

Authors:  D Santoli; W Hall; L Kastrukoff; R P Lisak; B Perussia; G Trinchieri; H Koprowski
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis.

Authors:  T Olsson; J Sun; J Hillert; B Höjeberg; H P Ekre; G Andersson; O Olerup; H Link
Journal:  Eur J Immunol       Date:  1992-04       Impact factor: 5.532

7.  A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum.

Authors:  P Gallo; M G Piccinno; B Tavolato; A Sidén
Journal:  J Neurol Sci       Date:  1991-02       Impact factor: 3.181

8.  Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry.

Authors:  L J Picker; M K Singh; Z Zdraveski; J R Treer; S L Waldrop; P R Bergstresser; V C Maino
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

9.  Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro.

Authors:  R L Hirsch; H S Panitch; K P Johnson
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

10.  Interferon production by cultured peripheral leucocytes of MS patients.

Authors:  G Vervliet; H Carton; E Meulepas; A Billiau
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

View more
  6 in total

1.  Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines.

Authors:  Yoshimitsu Doi; Shinji Oki; Tomoko Ozawa; Hirohiko Hohjoh; Sachiko Miyake; Takashi Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-11       Impact factor: 11.205

2.  Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients.

Authors:  Giovanni Frisullo; Francesco Angelucci; Massimiliano Mirabella; Marcella Caggiula; Katia Patanella; Viviana Nociti; Pietro Attilio Tonali; Anna Paola Batocchi
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

3.  Circulating lymphocyte subsets linked to intracellular cytokine profiles in normal humans.

Authors:  M Matsui; S Araya; H-Y Wang; N Onai; K Matsushima; T Saida
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

4.  Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.

Authors:  Sarah Benchabane; Mourad Belkhelfa; Houda Belguendouz; Sourour Zidi; Abdelhalim Boudjelida; Pierre Youinou; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2018-06-04       Impact factor: 4.473

5.  Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells.

Authors:  Nicolas Boivin; Joanie Baillargeon; Prenitha Mercy Ignatius Arokia Doss; Andrée-Pascale Roy; Manu Rangachari
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

6.  Differential T-cell responses in dogs with meningoencephalomyelitis of unknown origin compared to healthy controls.

Authors:  Renee Barber; James Barber
Journal:  Front Vet Sci       Date:  2022-08-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.